Abstract:The transient receptor potential vanilloid type 1 (TRPV1), a non-selective cation channel, is known for its essential role in the pathogenesis of various pain conditions such as nerve damage induced hyperalgesia, diabetic neuropathy and cancer pain. Therefore, TRPV1 is considered as a promising target for the development of new anti-inflammatory and analgesic drugs. In the present study, a theoretical study on the functionalities of the molecular interactions between 236 active ligands and TRPV1 was carried out, using three-dimensional quantitative structure-activity relationships (3D-QSAR), molecular docking and molecular dynamics (MD) simulation approaches. The ligand-based CoMSIA model (obtained by use of a random division method for splitting the training and test sets) exhibits optimum predictivity (Q(2) = 0.522, R(ncv)(2) = 0.935, R(pred)(2) = 0.839). The results show that the models are useful tools for the prediction of the test sets as well as newly designed structures against TRPV1 activity. In addition, to verify the rationality of the random division method for splitting the dataset, we also used a self-organizing map (SOM) division approach for establishing the QSAR models. Interestingly, the obtained optimal CoMSIA model based on the SOM division exhibits almost the same proper statistical results (Q(2) = 0.521, R(ncv)(2) = 0.929, R(pred)(2) = 0.829) as the random division-derived model, proving the reasonability of both division methods for building the models. The contour plots of molecular fields along with docking and MD simulation have identified several key structural requirements responsible for the activity. The present work provides extremely useful guidelines for future structural modifications of this class of compounds towards the development of superior TRPV1 antagonists. The new computational insights presented in this study are expected to be valuable for the guideline and development of new potent TRPV1 antagonists.

Progress in the development of TRPV1 small-molecule antagonists: Novel Strategies for pain management

De Novo Design of Peptidic Positive Allosteric Modulators Targeting TRPV1 with Analgesic Effects (adv. Sci. 17/2021)

TRPV1-Targeted Drugs in Development for Human Pain Conditions

Current insights and therapeutic strategies for targeting TRPV1 in neuropathic pain management

Targeting nociceptive transient receptor potential channels to treat chronic pain: current state of the field

De Novo Design of Peptidic Positive Allosteric Modulators Targeting TRPV1 with Analgesic Effects

A Structural Framework for the Polymodal Pain Sensor TRPV1

Discovery of Dual TRPA1 and TRPV1 Antagonists as Novel Therapeutic Agents for Pain

Transient receptor potential ankyrin 1 (TRPA1) modulators: Recent update and future perspective

Targeting TRP channels for pain relief: A review of current evidence from bench to bedside

Discovery of novel TRPV1 modulators through machine learning‐based molecular docking and molecular similarity searching

In silico research to assist the investigation of carboxamide derivatives as potent TRPV1 antagonists

Design, synthesis, and analgesia evaluation of novel Transient Receptor Potential Vanilloid 1 (TRPV1) agonists modified from Cannabidiol (CBD)

The Functional Regulation of TRPV1 and Its Role in Pain Sensitization.

Novel dual-target μ‐opioid and TRPV1 ligands as potential pharmacotherapeutics for pain management

[TRPV1: an Important Molecule Involved in the Peripheral Sensitization During Chronic Pain and Central Pain Modulation].

Identification of novel selective TRPV3 antagonists based on virtual screening, molecular docking and bioassay

TRPV1 analgesics disturb core body temperature via a biased allosteric mechanism involving conformations distinct from that for nociception

Dual Kv7.2/3-TRPV1 modulators inhibit nociceptor hyperexcitability and alleviate pain without target-related side effects

Human TRPV1 structure and inhibition by the analgesic SB-366791

Novel marine natural products as effective TRPV1 channel blockers